Cullinan Oncology

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

Meeting to highlight updated data from the Phase 1/2a study of CLN-081

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for Clinical Oncology (ASCO) meeting in June

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/.

Why Are Cullinan Oncology Shares Rising Today?

Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho's Acquisition of Cullinan Pearl

Data includes updated findings from Phase 1/2a study, including expanded patient cohort treated at a dose of 100 mg twice daily Data includes updated findings from Phase 1/2a study, including expanded patient cohort treated at a dose of 100 mg twice daily

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its management team will participate in the following virtual conferences in April.

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

Confirmed overall response rate improves to 41% at 100mg BID dose level

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, will provide a regulatory update on CLN-081 during a webinar being held Monday, March 28, 2022, at 4:30 p.m. ET.

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will be participating in the Barclays Healthcare Conference, being held in Miami, FL, March 15-17, 2022.

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, M.D., MPH, MBA will join the company as Chief Medical Officer and Anne-Marie (Annie) Martin, Ph.D., has been appointed to the Company's Board of Directors. Dr. Jones joins Cullinan Oncology from Bristol Myers Squibb where he held positions of increasing responsibility in oncology clinical development, most recently as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases. Dr. Martin brings to Cullinan Oncology over 25 years of translational medicine and clinical research expertise, and is currently Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline.

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D.

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink's 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.

Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference

Collaboration to identify and advance best-in-class HPK1 protein degraders

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January:

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

The stock price of Cullinan Oncology Inc (NASDAQ: CGEM) increased by 1.58% in the most recent trading session. This is why it happened.

Cullinan Oncology Stock (CGEM): Why The Price Increased

Shares of Cullinan Oncology Inc. CGEM, +6.87% shot up 9.9% in premarket trading Tuesday, after the biopharmaceutical company said its CLN-081 was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration for the treatment of non-small cell lunch cancer. A BTD expedites the development and review of drugs for the treatment of serious conditions, in which preliminary clinical evidence indicates the drug may demonstrate substantial improvement over currently available therapies.

Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA

Breakthrough Therapy Designation further supports the differentiated clinical profile of CLN-081 Breakthrough Therapy Designation further supports the differentiated clinical profile of CLN-081

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology's CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed on or after prior therapy.

Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16, 2021, at 8:00 a.m. ET.

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, today announced that it will be participating in the 4th Annual Evercore ISI HealthconX Conference from November 30th to December 2nd, 2021.

News for Cullinan Oncology Stock (CGEM)